JMP Securities Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $80 Price Target

CRINETICS PHARMACEUTICALS, INC. -0.98%

CRINETICS PHARMACEUTICALS, INC.

CRNX

51.40

-0.98%

JMP Securities analyst Jonathan Wolleben reiterates Crinetics Pharmaceuticals (NASDAQ: CRNX) with a Market Outperform and maintains $80 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via